Patients With mCRPC Need Effective and Tolerable Treatments Earlier
Unmet Need
Not an actual patient.
- A majority of patients die within 2 years of an mCRPC diagnosis1
- More than half of patients with mCRPC will receive only one life-prolonging therapy2
- mCRPC is associated with fast progression, which can disrupt patients’ lives2,3
What if you could provide a different, targeted therapy EARLIER?
mCRPC, metastatic castration-resistant prostate cancer.
Mechanism of Action
PLUVICTO DELIVERS DNA-BREAKING RADIATION DIRECTLY TO PSMA+ METASTASES4
Learn how PLUVICTO works
Based on in vitro/in vivo studies. Preclinical activity does not correlate with clinical outcomes.
PLUVICTO targets PSMA+ cells regardless of where they have metastasized (bone, nodal, or visceral)4
PLUVICTO is comprised of 2 key components: Lutetium-177, a cytotoxic radionuclide, and PSMA-617, a PSMA-targeting ligand.4-6
PLUVICTO binds to PSMA, a transmembrane protein expressed in prostate cancer cells. After binding to PSMA, PLUVICTO undergoes endocytosis and is internalized into the cell.4,5,7
Lutetium-177, the cytotoxic radionuclide of PLUVICTO, emits DNA-breaking radiation within the cell. The short path length of the radiation emitted by PLUVICTO, approximately 2 millimeters maximum, causes single- and double-stranded DNA breaks in targeted cells as well as surrounding cells, which can lead to cell death.4,8,9
PLUVICTO (plu-VICK-toh) describes a PSMA-targeted (P) lutetium-based (LU) radioligand therapy in PSMA+ mCRPC, where another option for patients is a victory4
Scanning to confirm PSMA+ mCRPC is key to identifying patients who may benefit from PLUVICTO4
Find information on PSMA-PET/CT scanning for your patients
CT, computed tomography; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.